Author(s):
Sanskar Bhardwaj, Rajendra Chauhan, Ankit Singh Tomar, Shusheel Pachori, Harshit Mishra, Hemant Mourya, Trapti Sahu, Navneet Garud
Email(s):
chauhan.rajendra56@gmail.com
DOI:
10.52711/0974-360X.2026.00208 
Address:
Sanskar Bhardwaj, Rajendra Chauhan*, Ankit Singh Tomar, Shusheel Pachori, Harshit Mishra, Hemant Mourya, Trapti Sahu, Navneet Garud
School of Studies in Pharmaceutical Sciences, Jiwaji University, Gwalior (M.P) India – 474011.
*Corresponding Author
Published In:
Volume - 19,
Issue - 3,
Year - 2026
ABSTRACT:
Monoclonal antibodies are type of immune cell, called as B cell which bind to specific targets known as antigens. One of the key advantages is their specificity and targeted action. Monoclonal antibodies play a crucial role in treating wide range of disease including cancer, autoimmune disorder and infectious disease. Origin of monoclonal antibodies in context of drug development are murine, chimeric, humanized and human monoclonal antibodies. The choice of origin significantly influences the drug development process, imparting timelines, costs and regulatory consideration. The FDA, as the primary regulatory authority in the United States, play a pivotal role in monoclonal antibodies drug approval. Variability in production can impart product quality; efficacy Regulatory agencies demand robust post marketing surveillance; monitoring mechanism to detect; address potential safety concern. Monoclonal antibodies market has valued at is anticipated to witness an impressive growth in the forecast period with a CAGR of 16.24% through 2028. In June 2021, Casivimab and Imdevimab are monoclonal antibodies designed to target the membrane spike protein of SARS-CoV-2, the virus responsible for year 2020 pandemic. High production costs, intellectual property barriers, and regulatory complexities contribute to the prohibitive pricing of these drugs, exacerbating healthcare disparities. Exploring innovative production platform, such as plant-based system or microbial fermentation, could significantly reduce production costs. These alternative platforms have the potential to enhance scalability, ease regulatory constraints, and facilitate the production of biosimilar monoclonal antibody drugs, thereby increasing global accessibility india.
Cite this article:
Sanskar Bhardwaj, Rajendra Chauhan, Ankit Singh Tomar, Shusheel Pachori, Harshit Mishra, Hemant Mourya, Trapti Sahu, Navneet Garud. Unveiling Hope: A Snapshot of CDSCO- Approved Monoclonal Antibodies in India. Research Journal Pharmacy and Technology. 2026;19(3):1445-3. doi: 10.52711/0974-360X.2026.00208
Cite(Electronic):
Sanskar Bhardwaj, Rajendra Chauhan, Ankit Singh Tomar, Shusheel Pachori, Harshit Mishra, Hemant Mourya, Trapti Sahu, Navneet Garud. Unveiling Hope: A Snapshot of CDSCO- Approved Monoclonal Antibodies in India. Research Journal Pharmacy and Technology. 2026;19(3):1445-3. doi: 10.52711/0974-360X.2026.00208 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-3-69
REFERENCES:
1. Makurvet, F. D. Biologics vs. Small Molecules: Drug Costs and Patient Access. Med. Drug Discov. 2021; 9: 100075. https://doi.org/10.1016/j.medidd.2020.100075.
2. Vaisman-Mentesh, A.; Gutierrez-Gonzalez, M.; DeKosky, B. J.; Wine, Y. The Molecular Mechanisms That Underlie the Immune Biology of Anti-Drug Antibody Formation Following Treatment With Monoclonal Antibodies. Front. Immunol. 2020; 11.
3. Joi et. al. Similar Biologics in India: A Story of Access or Potential for Compromise? Indian J. Med. Res. 2020; 152(5): 456–467. https://doi.org/10.4103/ijmr.IJMR_43_18.
4. Santos et. al. Advances and Challenges in Therapeutic Monoclonal Antibodies Drug Development. Braz. J. Pharm. Sci. 2018; 54: e01007. https://doi.org/10.1590/s2175-97902018000001007.
5. Zahavi, D.; Weiner, L. Monoclonal Antibodies in Cancer Therapy. Antibodies. 2020; 9(3): 34. https://doi.org/10.3390/antib9030034.
6. Rahalkar, H.; Cetintas, H. C.; Salek, S. Quality, Non-Clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines. Front. Pharmacol. 2018; 9.
7. Castelli, M. S.; McGonigle, P.; Hornby, P. J. The Pharmacology and Therapeutic Applications of Monoclonal Antibodies. Pharmacol. Res. Perspect. 2019; 7(6): e00535. https://doi.org/10.1002/prp2.535.
8. Lutterotti, A.; Martin, R. Getting Specific: Monoclonal Antibodies in Multiple Sclerosis. Lancet Neurol. 2008; 7(6): 538–547. https://doi.org/10.1016/S1474-4422(08)70110-8.
9. Doevendans, E.; Schellekens, H. Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies. Antibodies. 2019; 8(1): 21. https://doi.org/10.3390/antib8010021.
10. Posner wt. al. Monoclonal Antibodies: Past, Present and Future. In Concepts and Principles of Pharmacology; Barrett, J. E., Page, C. P., Michel, M. C., Eds.; Handbook of Experimental Pharmacology; Springer International Publishing: Cham, 2019; 260: 81–141. https://doi.org/10.1007/164_2019_323.
11. Rawat et. al. An Overview Of Monoclonal Antibodies And Their Therapeutic Applications. Nveo - Nat. Volatiles Essent. Oils J. Nveo. 2021: 4121–4130.
12. Wan, H. An Overall Comparison of Small Molecules and Large Biologics in ADME Testing. ADMET DMPK. 2016; 4: 1. https://doi.org/10.5599/admet.4.1.276.
13. Han, T. H.; Zhao, B. Absorption, Distribution, Metabolism, and Excretion Considerations for the Development of Antibody-Drug Conjugates. Drug Metab. Dispos.2014; 42(11): 1914–1920. https://doi.org/10.1124/dmd.114.058586.
14. Malik, B.; Ghatol, A. Understanding How Monoclonal Antibodies Work. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2023.
15. Kinch, M. S. An Overview of FDA-Approved Biologics Medicines. Drug Discov. Today. 2015; 20(4): 393–398. https://doi.org/10.1016/j.drudis.2014.09.003.
16. Singh et. al. Monoclonal Antibodies: A Review. Curr. Clin. Pharmacol. 2018; 13(2): 85–99. https://doi.org/10.2174/1574884712666170809124728.
17. Hansel et. al. The Safety and Side Effects of Monoclonal Antibodies. Nat. Rev. Drug Discov. 2010; 9(4): 325–338. https://doi.org/10.1038/nrd3003.
18. Dutta et. al. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It Is Not Only About Price! BioDrugs. 2020; 34(2): 159–170. https://doi.org/10.1007/s40259-019-00395-w.
19. Bayer, V. An Overview of Monoclonal Antibodies. Semin. Oncol. Nurs. 2019; 35(5): 150927. https://doi.org/10.1016/j.soncn.2019.08.006.
20. Winter, G.; Harris, W. J. Humanized Antibodies. Immunol. Today. 1993; 14(6): 243–246. https://doi.org/10.1016/0167-5699(93)90039-N.
21. Lu et. al. Development of Therapeutic Antibodies for the Treatment of Diseases. J. Biomed. Sci. 2020; 27(1): 1. https://doi.org/10.1186/s12929-019-0592-z.
22. Descotes, J. Immunotoxicity of Monoclonal Antibodies. mAbs. 2009; 1(2): 104–111. https://doi.org/10.4161/mabs.1.2.7909.
23. Pierpont, T. M.; Limper, C. B.; Richards, K. L. Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy. Front. Oncol. 2018; 8.
24. Somasundaram et. al. Progression of Continuous Downstream Processing of Monoclonal Antibodies: Current Trends and Challenges. Biotechnol. Bioeng. 2018; 115(12): 2893–2907. https://doi.org/10.1002/bit.26812.
25. Sharma et. al. Regulatory Perspective of International Agencies for Development of Biosimilar Products (Monoclonal Antibodies): An Overview. Ther. Innov. Regul. Sci. 2020; 54 (5): 965–977. https://doi.org/10.1007/s43441-020-00112-8.
26. Singh et. al. Biovigilance: A Global Perspective. Perspect. Clin. Res. 2019; 10(4): 155–162. https://doi.org/10.4103/picr.PICR_89_18.
27. Nair, G. G.; Fernandes, A. Patent Policies and Provisions Relating to Pharmaceuticals in India. JIPR. 2014; 191.
28. Kelley, B. Developing Therapeutic Monoclonal Antibodies at Pandemic Pace. Nat. Biotechnol. 2020; 38(5): 540–545. https://doi.org/10.1038/s41587-020-0512-5.
29. Cai, H. H.; Pandit, A. Therapeutic Monoclonal Antibodies Approved by FDA in 2021. Acta Sci. Microbiol. 2022; 81–83. https://doi.org/10.31080/ASMI.2022.05.1166.
30. Cai, H. H. Therapeutic Monoclonal Antibodies Approved by FDA in 2020. Clin. Res. Immunol. 2021; 4(1): 1–2.
31. Cai, H. H.; Pandit, A. A. Journal of Clinical and Experimental Immunology. 2023.
32. Kaplon et. al. Antibodies to Watch in 2023. mAbs15(1): 2153410. https://doi.org/10.1080/19420862.2022.2153410.
33. Rathore, A. Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India. PDA J. Pharm. Sci. Technol. 2012; 66(5): 393–393. https://doi.org/10.5731/pdajpst.2012.00886.
34. FitzGerald et. al. Benralizumab, an Anti-Interleukin-5 Receptor α Monoclonal Antibody, as Add-on Treatment for Patients with Severe, Uncontrolled, Eosinophilic Asthma (CALIMA): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. The Lancet. 2016; 388(10056): 2128–2141. https://doi.org/10.1016/S0140-6736(16)31322-8.
35. Kazazi-Hyseni et. al. Bevacizumab. The Oncologist. 2010; 15(8): 819–825. https://doi.org/10.1634/theoncologist.2009-0317.
36. Krämer, I.; Lipp, H.-P. Bevacizumab, a Humanized Anti-Angiogenic Monoclonal Antibody for the Treatment of Colorectal Cancer. J. Clin. Pharm. Ther. 2007; 32(1): 1–14. https://doi.org/10.1111/j.1365-2710.2007.00800.x.
37. Markham, A. Brolucizumab: First Approval. Drugs. 2019; 79(18): 1997–2000. https://doi.org/10.1007/s40265-019-01231-9.
38. Brolucizumab. https://go.drugbank.com/drugs/DB14864 (accessed 2024-01-22).
39. Crizanlizumab. https://go.drugbank.com/drugs/DB15271 (accessed 2024-01-23).
40. Blair, H. A. Crizanlizumab: First Approval. Drugs. 2020; 80(1): 79–84. https://doi.org/10.1007/s40265-019-01254-2.
41. Costa, B.; Vale, N. Dostarlimab: A Review. Biomolecules. 2022; 12(8): 1031. https://doi.org/10.3390/biom12081031.
42. Lamb, Y. N. Galcanezumab: First Global Approval. Drugs. 2018; 78(16): 1769–1775. https://doi.org/10.1007/s40265-018-1002-7.
43. Galcanezumab. https://go.drugbank.com/drugs/DB14042 (accessed 2024-01-23).
44. Smolen, J. S.; Emery, P. Infliximab: 12 Years of Experience. Arthritis Res. Ther. 2011; 13(1): S2. https://doi.org/10.1186/1478-6354-13-S1-S2.
45. Smith, D. A.; Minthorn, E. A.; Beerahee, M. Pharmacokinetics and Pharmacodynamics of Mepolizumab, an Anti-Interleukin-5 Monoclonal Antibody. Clin. Pharmacokinet. 2011; 50(4): 215–227. https://doi.org/10.2165/11584340-000000000-00000.
46. Robinson, D. S. Mepolizumab Treatment for Asthma. Expert Opin. Biol. Ther. 2013; 13(2): 295–302. https://doi.org/10.1517/14712598.2012.725717.
47. Ocrelizumab. https://go.drugbank.com/drugs/DB11988 (accessed 2024-02-05).
48. Hohlfeld, R.; Meinl, E. Ocrelizumab in Multiple Sclerosis: Markers and Mechanisms. Lancet Neurol. 2017; 16(4): 259–261. https://doi.org/10.1016/S1474-4422(17)30048-0.
49. Scott, L. J.; Lamb, H. M. Palivizumab: Drugs1999; 58(2): 305–311. https://doi.org/10.2165/00003495-199958020-00009.
50. Nguyen, C. M.; Jacob, S. E. Pembrolizumab. J. Dermatol. Nurses Assoc. 2017; 9(2): 95. https://doi.org/10.1097/JDN.0000000000000264.
51. Choi; Y.; Diefenbach; C. S. Polatuzumab Vedotin: A New Target for B Cell Malignancies. Curr. Hematol. Malig. Rep. 2020; 15(2): 125–129. https://doi.org/10.1007/s11899-020-00572-7.
52. Blick, S. K. A.; Keating, G. M.; Wagstaff, A. J. Ranibizumab. Drugs. 2007; 67(8): 1199–1206. https://doi.org/10.2165/00003495-200767080-00007.
53. Bandeira, L.; Lewiecki, E. M.; Bilezikian, J. P. Romosozumab for the Treatment of Osteoporosis. Expert Opin. Biol. Ther. 2017; 17(2): 255–263. https://doi.org/10.1080/14712598.2017.1280455.
54. Spesolimab. https://go.drugbank.com/drugs/DB15626 (accessed 2024-02-06).
55. Boekhout, A. H.; Beijnen, J. H.; Schellens, J. H. M. Trastuzumab. The Oncologist. 2011; 16(6): 800–810. https://doi.org/10.1634/theoncologist.2010-0035.
56. Wyant, T.; Fedyk, E.; Abhyankar, B. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab. J. Crohns Colitis. 2016; 10(12): 1437–1444. https://doi.org/10.1093/ecco-jcc/jjw092.
57. Smolen et. al. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. N. Engl. J. Med. 2022; 387(8): 715–726. https://doi.org/10.1056/NEJMoa2201302.
58. Mease, P. J. Adalimumab in the Treatment of Arthritis. Ther. Clin. Risk Manag. 2007; 3(1): 133–148. https://doi.org/10.2147/tcrm.s31133.
59. Nooka et. al. Daratumumab in Multiple Myeloma. Cancer2019; 125 (14), 2364–2382. https://doi.org/10.1002/cncr.32065.
60. Denosumab. https://go.drugbank.com/drugs/DB06643 (accessed 2024-01-23).
61. Alvarez-Argote, J.; Dasanu, C. A. Durvalumab in Cancer Medicine: A Comprehensive Review. Expert Opin. Biol. Ther. 2019; 19(9): 927–935. https://doi.org/10.1080/14712598.2019.1635115.
62. Evolocumab. https://go.drugbank.com/drugs/DB09303 (accessed 2024-01-23).
63. Pelechas, E.; Voulgari, P. V.; Drosos, A. A. Golimumab for Rheumatoid Arthritis. J. Clin. Med. 2019; 8(3): 387. https://doi.org/10.3390/jcm8030387.
64. Cameron, F.; Whiteside, G.; Perry, C. Ipilimumab. Drugs. 2011; 71(8): 1093–1104. https://doi.org/10.2165/11594010-000000000-00000.
65. Gunturi, A.; McDermott, D. F. Nivolumab for the Treatment of Cancer. Expert Opin. Investig. Drugs2015; 24 (2): 253–260. https://doi.org/10.1517/13543784.2015.991819.
66. Tarhini, A. A. Tremelimumab: A Review of Development to Date in Solid Tumors. Immunotherapy. 2013; 5(3): 215–229. https://doi.org/10.2217/imt.13.9.
67. John et. al. Amivantamab: A Narrative Drug Review. Cancer Res. Stat. Treat. 2023; 6(2): 261. https://doi.org/10.4103/crst.crst_166_23.
68. Syed, Y. Y. Amivantamab: First Approval. Drugs. 2021; 81(11): 1349–1353. https://doi.org/10.1007/s40265-021-01561-7.
69. Guo et. al. Teclistamab: Mechanism of Action, Clinical, and Translational Science. Clin. Transl. Sci. 2024; 17(1): e13717. https://doi.org/10.1111/cts.13717.
70. Grilo, A. L.; Mantalaris, A. The Increasingly Human and Profitable Monoclonal Antibody Market. Trends Biotechnol. 2019; 37(1): 9–16. https://doi.org/10.1016/j.tibtech.2018.05.014.